Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antidepressant |
| gptkbp:activeIngredient |
gptkb:imipramine
|
| gptkbp:approvedBy |
1950s
|
| gptkbp:ATCCode |
N06AA02
|
| gptkbp:brand |
gptkb:imipramine
|
| gptkbp:CASNumber |
50-49-7
|
| gptkbp:chemicalFormula |
C19H24N2
|
| gptkbp:contraindication |
recent myocardial infarction
hypersensitivity to imipramine |
| gptkbp:discoveredBy |
gptkb:Ciba-Geigy
|
| gptkbp:eliminationHalfLife |
11–25 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tofranil
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
norepinephrine reuptake inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
constipation
blurred vision weight gain drowsiness dry mouth urinary retention |
| gptkbp:usedFor |
gptkb:depression
enuresis |
| gptkbp:bfsParent |
gptkb:imipramine
|
| gptkbp:bfsLayer |
6
|